➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
AstraZeneca
Medtronic
Express Scripts
Moodys

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,829,013


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,829,013 protect, and when does it expire?

Patent 8,829,013 protects JAKAFI and is included in one NDA.

This patent has seventy-six patent family members in forty-one countries.

Summary for Patent: 8,829,013
Title:Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile
Abstract: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s): Rodgers; James D. (Landenberg, PA), Li; Hui-Yin (Hockessin, DE)
Assignee: Incyte Corporation (Wilmington, DE)
Application Number:14/256,311
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,829,013
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,829,013

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-001 Nov 16, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial FOR THE TREATMENT OF POLYCYTHEMIA VERA ⤷  Free Forever Trial
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-001 Nov 16, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS ⤷  Free Forever Trial
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-002 Nov 16, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial FOR THE TREATMENT OF POLYCYTHEMIA VERA ⤷  Free Forever Trial
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-002 Nov 16, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,829,013

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008266183 ⤷  Free Forever Trial
Brazil PI0814254 ⤷  Free Forever Trial
Canada 2689663 ⤷  Free Forever Trial
China 101932582 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Medtronic
Moodys
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.